Technology and the boundaries of the hospital: Three emerging technologies

Health Affairs

Volumn 23, Issue 6, 2004, Pages 149-156

  Goldsmith, Jeff ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; MEDICAL RESEARCH; MEDICAL SERVICE; PATIENT CARE; PATIENT MONITORING; REVIEW;

DELIVERY OF HEALTH CARE; HEALTH POLICY; HOSPITALS; HUMANS; TECHNOLOGY, MEDICAL; UNITED STATES;

EID: 8844246454     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.23.6.149     Document Type: Review

References (28)

1. R. Stevens, in Sickness and in Wealth American Hospitals in the Twentieth Century (Baltimore: Johns Hopkins University Press, 1989).
2. J. Goldsmith, Can Hospitals Survive: The New Competitive Healthcare Market (Chicago: Dow-Jones Irwin, 1982).
3. American Hospital Association, Hospital Statistics 2003 (Chicago: AHA, December 2003).
4. IMV's Medical Information Division, "Latest IMV Census of MRI Facilities Identifies 'Early Adopter' Sites of New Clinical Applications," Press Release, 20 April 2002, www.imvlimited .com/mid/pdf/MR01%20PR%20V1.pdf (18 August 2004).
5. IMV, "CT Sites Moving Quickly to Adopt Latest CT Multi-Slice Technology and Applications," Press Release, June 2002, www.imvlimited.com/mid/news_ctpr.html (18 August 2004).
6. Moody's Investors Service, "Not-for-Profit Healthcare: 2002 Outlook and Medians" (New York: Moody's, August 2002); Y. Igbal, "Megatrends in Outpatient Surgery," Outpatient Surgery Magazine, 3, no. 3 (2002): 28; and Health Care Advisory Board analysis of Verispan data, late 2001 (Yardley, Pennsylvania).
7. Moody's Investors Service, "Not-for-Profit Healthcare: 2002 Outlook and Medians" (New York: Moody's, August 2002); Y. Igbal, "Megatrends in Outpatient Surgery," Outpatient Surgery Magazine, 3, no. 3 (2002): 28; and Health Care Advisory Board analysis of Verispan data, late 2001 (Yardley, Pennsylvania).
8. Moody's Investors Service, "Not-for-Profit Healthcare: 2002 Outlook and Medians" (New York: Moody's, August 2002); Y. Igbal, "Megatrends in Outpatient Surgery," Outpatient Surgery Magazine, 3, no. 3 (2002): 28; and Health Care Advisory Board analysis of Verispan data, late 2001 (Yardley, Pennsylvania).
9. S.B. Liggett, "Pharmacogenetic Applications of the Human Genome Project," Nature Medicine 7, no. 3 (2001): 281-283.
10. K.A. Phillips et al., "Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review," Journal of the American Medical Association 286, no. 18 (2001): 2270-2279.
11. Roche Diagnostics, "Microarray ('DNA Chip') and Roche AmpliChip CYP450 Backgrounder," 2003, www.roche-diagnostics.com/media/pdf/ press_release/2003/background_amplichip_450 .pdf (18 August 2004).
12. J. Brockmoller et al., "Pharmacogenetic Diagnostics of Cytochrome P450 Polymorphisms in Clinical Drug Development and in Drug Treatment," Pharmacogenomics 1, no. 2 (2000): 125-151.
13. C. Arnst, "New Cancer Weapons Strut Their Stuff," Business Week Online, 10 May 2001, www .businessweek.com/technology/content/may 2001/tc20010510_835.htm (18 August 2004).
14. M.S. Hirsch et al., "Antiretroviral Drug Resistance Testing in Adults with HIV Infection," Journal of the American Medical Association 279, no. 4 (1998): 1984-1991; and J. Durant et al., "Drug-Resistance Genotyping in HIV-1 Therapy: The VIRADAPT Randomized Controlled Trial," Lancet 353, no. 9171 (1999): 2195-2199.
15. M.S. Hirsch et al., "Antiretroviral Drug Resistance Testing in Adults with HIV Infection," Journal of the American Medical Association 279, no. 4 (1998): 1984-1991; and J. Durant et al., "Drug-Resistance Genotyping in HIV-1 Therapy: The VIRADAPT Randomized Controlled Trial," Lancet 353, no. 9171 (1999): 2195-2199.
16. H.Z. Ring and D.L. Kroetz, "Candidate Gene Approach for Pharmacogenetic Studies," Pharmacogcnomics 3, no. 1 (2002): 47-56.
17. J.F. Dooley, "The Genomics Outlook to 2005: Transforming Pharmaceutical and Diagnostic Markets" (London: Reuters Business Insight, 2002).
18. S. Burrill, Biotech 2002: Life Sciences - Systems Biology, The Biotechnology Industry Sixteenth Annual Report (San Francisco: Burrill and Company, 2002), 65.
19. A. Persidis, "Tissue Engineering," Nature Biotechnology 18, no. 10 Supp. (2000): IT56-IT58.
20. D.J. Mooney and A.G. Mikos, "Growing New Organs," Scientific American 280, no. 4 (1999): 60-65.
21. G.Q. Daley, M.A. Goodell, and E.Y. Snyder, "Realistic Prospects for Stem Cell Therapeutics," Hematology, 2003, www.asheducationbook.org/cgi/ content/full/2003/1/398 (18 August 2004).
22. C. Becker, "Injecting Some Hope: Cell Therapy Could Lead to New Treatments for Congestive Heart Failure," Modern Healthcare 33, no. 32 (2003): 36-37.
23. C. Becker, "Remote Control," Modern Healthcare 32, no. 8 (2002): 40-44; M.J. Breslow et al., "Effect of an ICU Telemedicine Program on Clinical and Economic Outcomes," Critical Care Medicine 32, no. 1 (2004): 31-38; Medtronic, "Medtronic Begins Worldwide Rollout of Innovative Medtronic Carelink Programmer to Enhance Cardiac Care," Press Release, 18 March 2003, www .medtronic.com/newsroom/news_20020318c .html (18 August 2004); and Brian Rosenberg, medical director, VISICU, telephone interview, February 2003.
24. C. Becker, "Remote Control," Modern Healthcare 32, no. 8 (2002): 40-44; M.J. Breslow et al., "Effect of an ICU Telemedicine Program on Clinical and Economic Outcomes," Critical Care Medicine 32, no. 1 (2004): 31-38; Medtronic, "Medtronic Begins Worldwide Rollout of Innovative Medtronic Carelink Programmer to Enhance Cardiac Care," Press Release, 18 March 2003, www .medtronic.com/newsroom/news_20020318c .html (18 August 2004); and Brian Rosenberg, medical director, VISICU, telephone interview, February 2003.
25. C. Becker, "Remote Control," Modern Healthcare 32, no. 8 (2002): 40-44; M.J. Breslow et al., "Effect of an ICU Telemedicine Program on Clinical and Economic Outcomes," Critical Care Medicine 32, no. 1 (2004): 31-38; Medtronic, "Medtronic Begins Worldwide Rollout of Innovative Medtronic Carelink Programmer to Enhance Cardiac Care," Press Release, 18 March 2003, www .medtronic.com/newsroom/news_20020318c .html (18 August 2004); and Brian Rosenberg, medical director, VISICU, telephone interview, February 2003.
26. C. Becker, "Remote Control," Modern Healthcare 32, no. 8 (2002): 40-44; M.J. Breslow et al., "Effect of an ICU Telemedicine Program on Clinical and Economic Outcomes," Critical Care Medicine 32, no. 1 (2004): 31-38; Medtronic, "Medtronic Begins Worldwide Rollout of Innovative Medtronic Carelink Programmer to Enhance Cardiac Care," Press Release, 18 March 2003, www .medtronic.com/newsroom/news_20020318c .html (18 August 2004); and Brian Rosenberg, medical director, VISICU, telephone interview, February 2003.
27. R.A. Berger, "Total Hip Arthroplasty using the Minimally Invasive Two-Incision Approach," Clinical Orthopaedics 1, no. 417 (2003): 232-241; and L.T. Khoo et al., "Minimally Invasive Percutaneous Posterior Lumbar Interbody Fusion," Neurosurgery 51, no. 5 (2002): S2-166-S2-181.
28. R.A. Berger, "Total Hip Arthroplasty using the Minimally Invasive Two-Incision Approach," Clinical Orthopaedics 1, no. 417 (2003): 232-241; and L.T. Khoo et al., "Minimally Invasive Percutaneous Posterior Lumbar Interbody Fusion," Neurosurgery 51, no. 5 (2002): S2-166-S2-181.